Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
See attached my earlier post:
SOME INTERESTING POINTS TO NOTE29 Apr 2021 12:00
Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.
A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.
Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.
mathsprof,
Correct explanation given.
When the “ask” and “bid” have a larger spread this colour coding changes, as demand for buys are low. Buyers have to be careful when this happens.
An indirect warning in my opinion.
cjinvest,
Find attached a more detailed information for your reading.
Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.
A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.
Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.
bbrq648
cjinvest,
This was your 3rd post here.
What would you know about the work and effort put towards a fast, accurate and sensitive COVID-19 test by Paraytec team with the help of University of Sheffield Team headed by Prof. Carl Smythe. More than 12 months hard and dedicated work contributed to this testing.
So please don’t write some stupid things just for the sake of posting in this BB.
Another post explaining more details will follow just for you.
bbrq648
butch123,
You are a real deramper, purposefully writing speculative wrong reasons.
Who have asked you to post in this BB?
Are you invested here in BRH?
If so you would have known well about Prof. Carl Smythe of University of Sheffield heads the team working with Paraytec Team.
This itself proves you are here to spread rumours in this BB,
You are filtered.
bbrq648
Moorhay ,
You are filtered.
One shouldn’t think that he is smart and clever.
There are several smart and creative and clever characters in this board, whom are not only DYOR, and aware of the world, politics and economy of UK, but also the world.
Our product is going to be the best for COVID-19 Testing for the world and one have to have patience to prevail.
bbrq648
Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.
A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.
Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.
bbrq648
Moorhead,
Sorry Moorhey,
Don’t you also read the news that Checking using Existing LFTs to give green light by our government was a wrong decision and PHA didn’t agree with this decision making.
Who knows what is behind this?
You judge this.
Note:
The LFT tests only identify high viral loads, and don’t identify the pre-symptomatic and asymptomatic people with low viral loads.
bbrq648
19thHole,
Are you an investor here or deramping here?
It didn’t make any sense of posting here knowing uncertainty regarding BOD sale.
You need to do your own research (DYOR), prior to invest.
Please refer to my earlier post regarding BOD sales.
bbrq648
MarcEtMaker,
Yes, the weak sellers who are going to regret selling at this price.
However, this will help for a steady rise quickly.
Good chance to buy below 85p.
Hold on to your valuable shares, if you want to make the most profits.
bbrq648
butch123,
So, what brought you here?
We know very well when the manufacturing and orders to come.
After this expected RNS to arrive before COT this Friday. Furthermore, details regarding manufacturers JV, Trademark and orders will automatically come after the MHRA approval.
You don’t have to waste time here as our product is the fast, accurate and sensitive COVID-19 test.
Best in class, and can identify pre-symptomatic and asymptomatic cases to facilitate isolation.
Don’t compare other products here without finding the deficiencies of those products.
bbrq648